Difficulty: Medium
Average Score: 75%
Practice
You are evaluating a 6-year-old child with ALL on interim maintenance phase who has frequent mucositis and myelosuppression that needs frequent discontinuation of his treatment. Of the following, the MOST valuable test for this child is
Correct answer
B
Rationale
In this scenario, the most valuable test for the 6-year-old child with Acute Lymphoblastic Leukemia (ALL) experiencing mucositis and myelosuppression is pharmacogenetic testing of the thiopurine S-methyltransferase (TPMT) gene (Option B). This is crucial because TPMT gene testing helps determine the child's ability to metabolize thiopurine medications commonly used in ALL treatment, such as mercaptopurine. Children with ALL are often treated with these medications, and those with TPMT genetic variations are at a higher risk of developing severe toxicities. By identifying TPMT gene status, healthcare providers can personalize the child's treatment plan, adjust medication doses, and reduce the risk of adverse effects, ensuring more effective and safer treatment.
Option A (complete blood count) is a standard test for monitoring blood cell counts but does not provide specific information about drug metabolism like TPMT testing does. Option C (renal function test) is important for assessing kidney function but is not directly related to optimizing ALL treatment. Option D (bone marrow study) is valuable for assessing disease response and progression in ALL but does not provide information on drug metabolism or toxicity risk associated with thiopurine medications.
Understanding the importance of pharmacogenetic testing in pediatric oncology not only highlights the significance of personalized medicine but also emphasizes the need for comprehensive care in managing treatment-related complications in children with cancer. By integrating genetic testing into clinical practice, healthcare providers can enhance treatment outcomes, minimize risks, and improve the overall quality of care for pediatric patients with ALL.
Option A (complete blood count) is a standard test for monitoring blood cell counts but does not provide specific information about drug metabolism like TPMT testing does. Option C (renal function test) is important for assessing kidney function but is not directly related to optimizing ALL treatment. Option D (bone marrow study) is valuable for assessing disease response and progression in ALL but does not provide information on drug metabolism or toxicity risk associated with thiopurine medications.
Understanding the importance of pharmacogenetic testing in pediatric oncology not only highlights the significance of personalized medicine but also emphasizes the need for comprehensive care in managing treatment-related complications in children with cancer. By integrating genetic testing into clinical practice, healthcare providers can enhance treatment outcomes, minimize risks, and improve the overall quality of care for pediatric patients with ALL.